Drug Profile
Research programme: protein kinase C modulators - KAI Pharmaceuticals
Alternative Names: KAI-9706; KP-2018Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator KAI Pharmaceuticals
- Class Peptides
- Mechanism of Action Protein kinase C beta inhibitors; Protein kinase C delta inhibitors; Protein kinase C epsilon modulators; Protein kinase C gamma inhibitors; Protein kinase C modulators; Protein kinase C theta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- No development reported Autoimmune disorders; Cancer; Cardiovascular disorders; Diabetic retinopathy; Eye disorders; Neuropathic pain; Transplant rejection
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Diabetic-retinopathy in USA (Ophthalmic)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Eye-disorders in USA (Ophthalmic)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Neuropathic-pain in USA (Parenteral)